Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Mechanism of Action

Entrectinib has activity against anaplastic lymphoma kinase (ALK), ROS1, and TRKA, TRKB, and TRKC proteins [1-5]. Preclinical studies have demonstrated that entrectinib can cross the blood–brain barrier [3, 6, 7]. On this basis, entrectinib is thought to be able to target brain metastases and primary brain tumours.

The activity of entrectinib across a variety of kinases is shown in the following table, which summarises the IC50 values for entrectinib inhibition of kinase activity [4].

Table 9: Entrectinib Inhibition of Kinase Activity [4]


IC50 (nmol/L)











Preclinical studies found that entrectinib completely inhibited ALK and STAT3 protein phosphorylation after administration in vivo [4]. In addition, entrectinib induced complete tumour regression in mouse tumour models (including TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumours, and ALK-dependent models from different tissue origins, including a CNS lung cancer metastasis model).


  1. Chen Y, Chi P. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 2018; 11: 78.
  2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.
  3. Menichincheri M, Ardini E, Magnaghi P et al. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. J Med Chem 2016; 59: 3392-3408.
  4. Ardini E, Menichincheri M, Banfi P et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther 2016; 15: 628-639.
  5. Sartore-Bianchi A, Ardini E, Bosotti R et al. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl Cancer Inst 2016; 108.
  6. Drilon A, Siena S, Ou SI et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017; 7: 400-409.
  7. Demetri GD, Paz-Ares L, Farago AF et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology 2018; 29: mdy424.017-mdy424.017, https://doi.org/410.1093/annonc/mdy1424.1017.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.